Related Experiment Video

Updated: Jun 16, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

[Use of midazolam for refractory status epilepticus in children]

M-E Lampin1, A Dorkenoo, M-D Lamblin

  • 1Service de réanimation pédiatrique, CHRU de Lille, Lille cedex, France.

Revue Neurologique
|February 23, 2010
PubMed

Insights

Midazolam effectively treats refractory status epilepticus (RSE) in children, showing lower morbidity and mortality compared to other treatments. This study highlights midazolam as a promising first-line option for pediatric RSE management.

Area of Science:

  • Pediatric intensive care
  • Neurology
  • Emergency medicine

Background:

  • Refractory status epilepticus (RSE) in children is associated with significant morbidity and mortality.
  • Current treatment options for RSE carry substantial risks.
  • There is a need for effective and safer treatments for pediatric RSE.

Purpose of the Study:

  • To evaluate the efficacy and safety of midazolam as a first-line treatment for refractory status epilepticus (RSE) in children.
  • To compare the outcomes of midazolam treatment with other antiepileptic drugs in pediatric RSE.

Main Methods:

  • Retrospective analysis of 29 children with RSE admitted to a pediatric intensive care unit (PICU).
  • Midazolam was used as the first-line treatment (bolus followed by continuous infusion).
  • Thiopental was used as a second-line treatment in cases of midazolam failure.

Main Results:

  • Midazolam successfully controlled RSE in 58% of pediatric patients.
  • The mean delay to RSE cessation was 48+/-65 minutes.
  • Hypotension occurred in 8% of midazolam-treated patients versus 71% of thiopental-treated patients. No deaths occurred in the midazolam group.

Conclusions:

  • Midazolam is an efficient and safe first-line treatment for refractory status epilepticus in children.
  • Treatment with midazolam appears to be associated with lower morbidity and mortality rates compared to other antiepileptic drugs.
  • Midazolam offers a favorable risk-benefit profile for managing pediatric RSE.
Abstract

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...